Larkin Cristina 4
4 · Spero Therapeutics, Inc. · Filed Feb 3, 2021
Insider Transaction Report
Form 4
Larkin Cristina
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-01+57,432→ 57,432 totalExercise: $19.18Exp: 2031-02-01→ Common Stock (57,432 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on February 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.